The following is from B.K. Keayla*, December 5-7, 1997 "TRIPS Agreement on Patent Laws: Impact on Pharmaceuticals and Health for All," paper presented at the International Conference on Global Health Law, organised by The Indian Law Institute in collaboration with the World Health Organization, with subsequent updates on prices
|
Table 10 Price Comparisons of medicines (Prices converted into Indian Rupees) | ||||||
|
Drugs/
Brands presenation |
Company | India | Pakistan | Indonesia | UK | USA |
| Ranitidine/(Zantac)
300 mg x 10 |
Glaxo | 17.39 | 241.44 | 658.36 | 603.24 | 1200.80 |
| Times costlier | (13.88) | (37.86) | (34.69) | (69.05) | ||
| Diclofanic
Sodium /
(Voveran)
50 mg x1 0s |
Ciba-Geigy | 6.49 | 55.62 | 177.18 | 120.12 | 402.80 |
| Times costlier | (8.57) | (27.30) | (18.51) | (62.06) | ||
| Piroxicam /
(Dolonex/ Feldene)
20 mg x 10s |
Pfizer | 24.64 | 72.50 | 218.45 | 1064.80 | 1064.80 |
| Times costlier | (2.94) | (8.86) | (5.73) | (43.21) | ||
|
One US $ = Rs.40 One UK pound = Rs.66 Prices compiled in April 1998 | ||||||
* Mr. Keayla is the Convenor, National Working Group on Patent Laws, and Co-ordinator, Forum of Parliamentarians on Intellectual Property and W.T.O. Issues, New Delhi.